Zimmer Biomet Holdings Inc. (ZBH) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, ZBH scores 71 out of 100, a B- grade with the verdict label "Roarable Buy — Sound Institutional Accumulation." The five pillars are:

• Fundamental Cash Engine: 12 / 20. Per the RQD rating, this pillar reflects ROIC of 4.6% and an FCF yield of 7.92%. For a prospective investor, the cash generation is meaningful relative to the price, but the low ROIC indicates that the return on invested capital is modest, which limits how much of the cash engine is translating into value creation.
• Whale 13F Flow: 15 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The score suggests institutional interest is constructive, though the source data does not itemize specific 13F holdings (see Analyst View section).
• Insider Conviction: 15 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The score indicates a moderately supportive insider signal; the underlying transactions are not itemized in the source data.
• Macro Regime Fit: 15 / 20. Per the RQD rating, this pillar reflects a beta of 1.02 and sector sensitivity. A beta near 1.0 implies the stock has historically moved roughly in line with the broad market, so it offers neither a defensive profile nor a high-volatility profile.
• Forensic Balance Sheet: 14 / 20. Per the RQD rating, this pillar reflects an Altman Z of 2.42, Piotroski F of 8/9, and Debt/Equity of 0.55. These are relatively healthy readings and are the strongest supporting factor in the rating.

Investor implications: The rating's upside drivers are the balance sheet quality, institutional support, and reasonable cash yield. The valuation tradeoff is that the stock trades at a P/E (TTM) of 26.4 and EV/EBITDA of 19.3 against a modest ROIC of 4.6%, so the market price already embeds significant expectations relative to current returns on capital. This is an analytical framing, not personalized financial advice.

Per the SEC financials, revenue grew from $7394.2M (FY 2023) to $8231.5M (FY 2025), while net income declined from $1024.0M to $705.1M over the same span. Reported debt rose from $2392.7M to $6932.0M across the three periods. Per the RQD rating and market data, ROIC is 4.6%, net margin is 8.6%, the Altman Z-Score is 2.42, the Piotroski F-Score is 8/9, and Debt/Equity is 0.55. The Z-Score and F-Score readings are relatively supportive, while the declining net income and rising debt are the trends a careful reader should weigh alongside them.

• What specific products and end markets generate ZBH's revenue, and how is the business segmented?
• Why did net income decline from FY 2023 to FY 2025 while revenue increased, and what drove the rise in debt from $2392.7M to $6932.0M?
• What is the reason behind the 3.0% share decline flagged in the GuruFocus headline, and is it linked to a fundamental event?
• How do the reported EPS figures (listed as N/A in the financials) reconcile with the EPS (TTM) of 3.7 in market data?
• What institutional and insider transactions underpin the Whale 13F Flow and Insider Conviction pillar scores?